Revolution Medicines starts shipping experimental pancreatic cancer drug Life-extending data for daraxonrasib create high patient demand even without FDA approval

https://www.statnews.com/2026/05/30/pancreatic-cancer-daraxonrasib-revolution-medicines-early-access-asco-2026/ By Adam FeuersteinMay 30, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.